1-5 of 5
Nicole Winchell
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Characteristics, Treatment Patterns, and Outcomes in Primary Cutaneous Gamma Delta T Cell Lymphoma (PCGDTCL): A Real World Multi-Institutional Analysis of a Rare Malignancy

Kevin A. David, MD, Melissa Pulitzer, MD, Joan Guitart, MD, Maria Estela Martinez-Escala, MD, Shamir Geller, MD, Yaqun Wang, N. Nora Bennani, MD, Kay M. Ristow, BS, Daniel J. Landsburg, MD, Nicole Winchell, Paul Haun, MD, Pamela Allen, MDMSc, Basem M. William, MRCP,MD, Nathan Denlinger, MS, DO, Neha Mehta-Shah, MD, Ryan A. Wilcox, MD PhD, Alexandra Hristov, Tatyana A. Feldman, MD, Alex Weller, Andrew M. Evens, DO, MSc, Steven M. Horwitz, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4028.
https://doi.org/10.1182/blood-2019-130223
Published: 2019
Journal Articles

Characteristics and Outcomes of Ibrutinib-Associated Musculoskeletal Toxicities in CLL Patients

Joanna Rhodes, MD, Anthony R. Mato, MD MSCE, Nicole Winchell, Kaitlin Kennard, RN, BSN, James Nathan Gerson, MD, Daniel J. Landsburg, MD, Sunita Dwivedy Nasta, MD, Jakub Svoboda, MD, Stephen J. Schuster, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4418.
https://doi.org/10.1182/blood-2018-99-115377
Published: 2018
Journal Articles

Sequential Anti-CD19 Directed Chimeric Antigen Receptor Modified T-Cell Therapy (CART19) and PD-1 Blockade with Pembrolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

Elise A. Chong, MD, Jakub Svoboda, MD, Sunita Dwivedy Nasta, MD, Daniel J. Landsburg, MD, Nicole Winchell, Ellen Napier, NP, Anthony R. Mato, MD MSCE, J. Joseph Melenhorst, PhD, Marco Ruella, MD, Simon F Lacey, PhD BS, Carl H June, MD, Stephen J. Schuster, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4198.
https://doi.org/10.1182/blood-2018-99-119502
Published: 2018
Journal Articles

Treatment with Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) Results in Durable Remissions in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphomas of Germinal Center and Non-Germinal Center Origin, "Double Hit" Diffuse Large B Cell Lymphomas, and Transformed Follicular to Diffuse Large B Cell Lymphomas

Stephen J. Schuster, MD, Jakub Svoboda, MD, Sunita Dwivedy Nasta, MD, Elise A. Chong, MD, Nicole Winchell, Daniel J. Landsburg, MD, David L. Porter, MD, Anthony R. Mato, MD, Honore T Strauser, April M. Schrank-Hacker, Mariusz A Wasik, MD, Simon Francis Lacey, PhD BS, Jan Joseph Melenhorst, PhD, Anne Chew, PhD, Jens Hasskarl, MD PhD, Katherine T. Marcucci, PhD, Bruce L Levine, PhD, Carl H June, MD
Journal: Blood
Blood (2016) 128 (22): 3026.
https://doi.org/10.1182/blood.V128.22.3026.3026
Published: 2016
Journal Articles

Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Poor Prognosis, Relapsed or Refractory CD19+ Follicular Lymphoma: Prolonged Remissions Relative to Antecedent Therapy

Elise A. Chong, MD, Jakub Svoboda, MD, Sunita Dwivedy Nasta, MD, David L. Porter, MD, Nicole Winchell, Daniel J. Landsburg, MD, Anthony R. Mato, MD, Simon F. Lacey, PhD, Jan J. Melenhorst, PhD, Anne Chew, PhD, Jens Hasskarl, MD PhD, Katherine T. Marcucci, PhD, Bruce L Levine, PhD, Carl H June, MD, Stephen J. Schuster, MD
Journal: Blood
Blood (2016) 128 (22): 1100.
https://doi.org/10.1182/blood.V128.22.1100.1100
Published: 2016